In particular, a drug called Evusheld could offer protection for people who are vulnerable – but the UK isn’t offering it.
Academic rigour, journalistic flair
Articles on COVID antivirals
Displaying all articles
Analysis of Victoria’s winter COVID wave found Paxlovid and Lagevrio reduced the risk of hospitalisation and death. The results were better for Paxlovid, but not everyone can take it.
This guidance replaces previous conditional recommendations for the use of these drugs and is based on emerging evidence that they’re not likely to work against omicron.
We hear a lot about drug-resistant bacteria. The same thing can happen with viruses.
After testing positive for COVID, your medicine prescription will depend on the severity of your symptoms and any other health conditions you have.
Based on certain criteria, New Zealand is clearly ‘winning’. But getting policy settings right over the long haul is about more than just having the most favourable assessment on selected criteria.
Here’s who is eligible, the benefits and side effects to consider.
Job Board
-
Head of School, Humanities
-
Research Officer - Structural Biology of E3 Ubiquitin Ligases
-
Policy and Research Project Manager
-
Lecturer in Linguistics and Applied Linguistics
-
Senior Lecturer/ Associate Professor, Economics
Top contributors
-
Professor of Cancer Virology, University of Leeds
-
Director, Evidence and Methods, National COVID-19 Clinical Evidence Taskforce; Associate Professor (Research), Cochrane Australia, School of Population Health and Preventive Medicine, Monash University, Monash University
-
Director, WHO Collaborating Centre for Viral Hepatitis, The Peter Doherty Institute for Infection and Immunity
-
Associate Professor of the Sydney Pharmacy School, University of Sydney
-
Deputy Program Director, Health Security and Pandemic Preparedness, Burnet Institute
-
Professor of Public Health, University of Otago
-
Professor of Epidemiology, Population Interventions Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne
-
Adjunct Clinical Professor, Monash University
-
Associate Professor in Viral Immunology, University of Birmingham
-
Professor of general practice, Bond University
-
Pharmacist and PhD Candidate, University of Sydney
-
Monash University
-
A/Professor, paediatrician, infectious diseases physician and clinical pharmacologist, Murdoch Children's Research Institute
-
NHMRC Leadership Fellow UQ Centre for Clinical Research, The University of Queensland
-
Centre Acting Director, WHO Collaborating Centre for Viral Hepatitis, Victorian Infectious Diseases Reference Laboratory
